Morrison AC et al. 17 June 2021

Efficacy of a Spatial Repellent for Control of *Aedes*-Borne Virus Transmission:

A Cluster Randomized Trial in Iquitos, Peru

Amy C. Morrison, Ph.D.^{1,2+}, Robert C. Reiner Jr., Ph.D.³⁺, William H. Elson, M.B.B.S.⁴, Helvio Astete, M.S.², Carolina Guevara, M.S.², Clara del Aguila, B.S.⁵, Isabel Bazan, M.D.², Crystyan Siles, M.D.², Patricia Barrera, M.S.², Anna B. Kawiecki, M.S.¹, Christopher M. Barker, Ph.D.¹, Gissella M. Vasquez, Ph.D.⁶, Karin Escobedo-Vargas, B.S.⁶, Carmen Flores-Mendoza, Ph.D.⁶, Alfredo A. Huaman, B.S.², Mariana Leguia, Ph.D.⁷, Maria E. Silva, Ph.D.², Sarah A. Jenkins, Ph.D.², Wesley R. Campbell, M.D.², Eugenio J. Abente, Ph.D.², Robert D. Hontz, Ph.D.², Valerie A. Paz-Soldan, Ph.D.⁸, John P. Grieco, Ph.D.⁹, Neil F. Lobo, Ph.D.⁹⁺, Thomas W. Scott, Ph.D.⁴⁺, and Nicole L. Achee, Ph.D.⁹⁺

¹ Department of Pathology, Microbiology, and Immunology, School of Veterinary Medicine, University of California, Davis, California, USA

² Department of Virology and Emerging Infectious Diseases, U.S. Naval Medical Research Unit No. 6, Lima, Peru

³ Department of Health Metrics Sciences, University of Washington, Seattle, Washington, USA

⁴ Department of Entomology and Nematology, University of California, Davis, California, USA

⁵ Dirección General de Saneamiento Ambiental (DIGESA), Calle Alzamora 410, Iquitos, Peru

⁶ Department of Entomology, U.S. Naval Medical Research Unit No. 6, Lima, Peru

Morrison AC et al. 17 June 2021

25 ⁷ Genomics Laboratory, Pontificia Universidad Católica del Perú, Av. Universitaria
26 1801, San Miguel, Lima, Peru

27 ⁸ Department of Global Community Health and Behavioral Sciences, Tulane School
28 of Public Health and Tropical Medicine, New Orleans, Louisiana, USA

29 ⁹ Department of Biological Sciences, Eck Institute for Global Health, University of
30 Notre Dame, 239 Galvin Life Sciences Center. Notre Dame, Indiana, USA

31

32

33 *Indicates equal seniority

34

35 *Corresponding author:

36 Nicole L. Achee, PhD

37 Research Professor

38 Eck Institute for Global Health

39 Department of Biological Sciences

40 239 Galvin Life Science Center

41 Notre Dame, Indiana 46556

42 Ph: 574.631.1561

43 Email: nachee@nd.edu

44

45

46

47

Morrison AC et al. 17 June 2021

ABSTRACT

Background: Over half the world's population is at risk for viruses transmitted by *Aedes* mosquitoes, such as, dengue and Zika. The primary vector, *Aedes aegypti*, thrives in urban environments. Despite decades of effort, cases and the geographic range of *Aedes*-borne viruses (ABV) continue to expand. Rigorously proven vector control interventions that measure protective efficacy against ABV diseases is limited to *Wolbachia* in a single trial in Indonesia, and do not include any chemical intervention. Spatial repellents, a new option for efficient deployment, are designed to decrease human exposure to ABV by releasing active ingredients into the air that disrupt mosquito-human contact.

Methods: A parallel, cluster-randomized controlled trial was conducted in Iquitos, Peru to quantify the impact of a transfluthrin-based spatial repellent on human ABV infection. From 2,907 households across 26 clusters (13 per arm), 1,578 participants were assessed for seroconversion (primary endpoint) by survival analysis. Incidence of acute disease was calculated among 16,683 participants (secondary endpoint). Bi-monthly adult mosquito collections were conducted to compare *Ae. aegypti* abundance, blood-fed capture rate and parity status through mixed effect difference-in-difference analyses. This trial is registered with ClinicalTrials.gov, number NCT03553277.

Findings: The spatial repellent significantly reduced ABV infection by 34·1% (95% CI 6·9%, ∞); $p = 0·0236$, $z=1·98$). *Aedes aegypti* abundance and blood-fed capture

Morrison AC et al. 17 June 2021

69 rates were significantly reduced by 28·6% (95% CI 24·1%, ∞); z=-9·11) and 12·4%
70 (95% CI 4·2%, ∞); z=-2·43), respectively.

71 Interpretations: Our trial provides the first conclusive evidence of significant protective
72 efficacy by any chemical vector control intervention, in this case a spatial repellent, to
73 reduce the risk of ABV transmission. Results support vector control as a beneficial
74 component to ABV disease prevention.

75 Funding: Bill & Melinda Gates Foundation, Military Infectious Disease Program
76 (MIDRP), Defense Threat Reduction Agency (DTRA), and US National Institutes of
77 Health.

Morrison AC et al. 17 June 2021

Introduction

Aedes-borne viral diseases (ABVD) [e.g., dengue (DENV), chikungunya (CHIKV), Zika (ZIKV), and yellow fever (YF)] are devastating, expanding global public health threats that disproportionally affect low- and middle-income countries. Currently, the primary means for ABVD prevention is controlling the primary mosquito vector, *Aedes aegypti*. Existing vector control interventions, however, have failed to prevent ABV transmission and epidemics. Dengue alone, one of the most rapidly increasing vector-borne infectious diseases,^{1,2} with four billion people at risk of infection annually,³ results in ~400 million infections each year.²

There is an urgent need to develop evidence-based guidance for the use of new and existing ABV vector control tools. The evidence-base for vector control against ABVs is weak, despite considerable government investments in WHO-recommended control of larval habitats (larviciding, container removal) and ultra-low volume (ULV) insecticide spraying.⁴⁻⁸ These strategies continue to be implemented despite the lack of rigorously generated data from controlled clinical trials demonstrating they reduce ABV infection and disease.⁹ The only ABV intervention with a proven epidemiological impact in a cluster randomized control trial (cRCT) assessed community mobilization to reduce mosquito larval habitats.¹⁰ A recent test-negative trial with *Wolbachia*-infected mosquitoes reported a significant reduction of dengue illness in Indonesia.¹¹

Spatial repellents (SR) are devices that contain volatile active ingredients that disperse in air. The active ingredients can repel mosquitoes from entering a treated

Morrison AC et al. 17 June 2021

space, inhibit attraction to human host cues or disrupt mosquito biting and blood feeding behavior, and, thus, interfere with mosquito-human contact.^{12–14} Any of these outcomes reduce the probability of pathogen transmission. Pyrethroid-based spatial repellents have shown efficacy in reducing malaria infections in China¹⁵ and Indonesia.¹⁶ There have, however, been no clinical trials evaluating the protective efficacy of spatial repellents against ABV infection or disease.

To generate evidence for public health consideration we conducted a parallel, cluster-randomized controlled trial (cRCT) to quantify the epidemiological impact of a transfluthrin-based spatial repellent against ABV transmission in Iquitos, Peru.

Methods

The trial is registered at clinicaltrials.gov (NCT03553277).

ETHICAL STATEMENT

Our study protocol (#NAMRU6.2014.0021, Supplementary Information (SI)) was approved by the U.S. Naval Medical Research Unit No. 6 (NAMRU-6) Institutional Review Board (IRB), which includes Peruvian representation and complies with US Federal and Peruvian regulations governing the protections of human subjects, and the Regional Health Authority (DIRESA), the local branch of the Peruvian Ministry of Health. IRB authorization agreements were established between the NAMRU-6, the University of Notre Dame (Sponsor), the University of California at Davis, and the University of Washington.

Morrison AC et al. 17 June 2021

124

125 TRIAL DESIGN

126 Detailed study methods are provided in the SI.

127

128 Our trial was conducted from June 2015 through March 2019 in the Iquitos and
129 Punchana Districts of Iquitos, Peru (Figure 1, SI Section 1.1). Clusters were selected
130 in January 2015. Enrollment began June 2015. Participation included: 1) a house
131 census, 2) disease surveillance, 3) annual blood draws, 4) bi-monthly entomological
132 surveys, and 5) intervention application in the house. Epidemiological monitoring and
133 entomological surveillance lasted from February 2016 through March 2019 (Figure 2).

134

135 Our main objective was to demonstrate and quantify the protective efficacy (PE) of a
136 SR in reducing ABV infection incidence in a human cohort. Qualifying participants
137 were individuals in a participating house who were seronegative or had a monotypic
138 DENV antibody response when they entered the trial. Assuming the probability of
139 seroconversion for seronegative or monotypic individuals was 10% with a coefficient
140 of variation of 0.25, and an alpha of 5%, we estimated we would need 26 clusters (13
141 per arm) with approximately 60 qualifying individuals to achieve a power of 80% to
142 detect a reduction in the odds of 30%.

143

144 The primary endpoint was ABV seroconversion, as measured by DENV- or ZIKV-
145 specific neutralizing antibodies, in blood from children ≥ 2 years to ≤ 18 years. To
146 increase the pool of baseline seronegative participants, we expanded screening to

Morrison AC et al. 17 June 2021

≥18 years. Secondary endpoints were clinically apparent laboratory confirmed ABV disease and indoor female *Ae. aegypti*: 1) abundance, 2) blood-fed status (proxy for human-biting rates), and 3) parity status (proxy for age-structure). Participants followed for seroconversion were the ‘longitudinal cohort’ and those followed for disease were the ‘febrile surveillance cohort’.

RANDOMIZATION AND INTERVENTION

A total of 26 clusters (13 per arm) each with approximately 140 households (60 qualifying participants) were randomly allocated in August 2016 to receive SR or placebo intervention by the external statistician serving on the Data Safety Monitoring Board (DSMB) using a random number generator (<https://www.random.org>) (SI Section 1.2.1). Investigators, research staff, and study participants were blinded to cluster allocation. Our intervention was a transfluthrin passive emanator designed and produced by SC Johnson (Racine, WI), replaced at 2-week intervals, as described previously (Figure S1, SI Section 1.3.2).¹⁶ Spatial repellent and placebo intervention had identical packaging and were deployed in houses by study personnel using a blinded coding scheme. The placement of the intervention followed manufacturer specifications for indoor use conditions.

SEROCONVERSION AND DISEASE SURVEILLANCE

Recruitment for the longitudinal cohort focused on children because they were likely to be antibody test-negative or monotypic at baseline, which would facilitate interpretation of laboratory assays, and less mobile than adults¹⁷, thus spending more

Morrison AC et al. 17 June 2021

time in their houses or their assigned cluster. Baseline blood samples were obtained within 2 weeks before or after initial intervention deployment. As new families moved into the study area, they were recruited to participate, resulting in longitudinal participant enrollment throughout the interval between Baseline (B), First (F), and Second/Final (S) longitudinal blood draws (Figure 3). Samples were tested by microneutralization enzyme immunoassay (MNT) for seroconversion to each DENV serotype and ZIKV (SI Sections 1.3.3.1 and 1.3.4.1). Only participants that provided at least 2 blood samples were included in final analyses.

The febrile surveillance cohort was recruited by nurse technicians during door-to-door wellness starting with the first week of intervention deployment. Suspected cases exhibited axillary temperature of $\geq 37.5^{\circ}\text{C}$ or, for suspected ZIKV infection, absence of fever but presence of rash, arthralgia, arthritis, or non-purulent conjunctivitis for $\leq$ five days. Participants meeting these criteria provided acute and convalescent (14–21 days later) serum samples and were monitored clinically daily. Acute serum samples were tested for viral RNA by PCR (DENV and ZIKV; SI Sections 1.3.3.2-1.3.3.4) and by ELISA for DENV IgM (SI Sections 1.3.3.5, 1.3.4.2).

ENTOMOLOGICAL ENDPOINTS

Indoor Prokopack aspirations¹⁸ were conducted in all consented homes at time of first intervention deployment and subsequent intervention replacement; i.e., two-week intervals. Adult mosquitoes were transported to the NAMRU-6 Iquitos laboratory, sedated at 4°C , identified to species and sex, counted by date and house. Up to 30

Morrison AC et al. 17 June 2021

female *Ae. aegypti* per household per collection were examined for blood meal status and scored as unfed, blood-fed (fully engorged, half-engorged, or trace amounts), or gravid¹⁹. Standard insecticide resistance assays were used to assess vector susceptibility to transfluthrin one-year into the trial (SI Section 1.3.5.2).

SAFETY MONITORING

Adverse events (AEs) and serious adverse events (SAEs) were actively collected throughout the trial during surveillance follow-up and entomological surveys (SI Section 1.3.6). Reported AEs were investigated by study staff and appropriate care was recommended by a study physician within 24 hours. Safety reporting to the NAMRU-6 IRB was managed by UC Davis in accordance with the approved protocol. Quarterly reports summarizing reported AEs and SAEs were reviewed by the DSMB for trial safety assessment.

STATISTICAL ANALYSIS

Details of our analytical approach are provided in the statistical analysis plan (SAP) and SI Section 1.5. All analyses were conducted by RCR using R 3.6.1 (R Core Team)²⁰ and the lme4²¹ and survival²² packages. No correction for multiple testing was performed for secondary endpoint analyses and, as such, in accordance with CONSORT guidelines, we do not present p-values.

The primary analysis was an intent-to-treat (ITT) assessment of ABV seroconversion for all qualifying participants per treatment assignment who were >2 years to <18

Morrison AC et al. 17 June 2021

years of age. Due to the rolling nature of enrollment, we used a survival analysis with a proportional hazards model and exponential distribution assumption for the baseline hazard (i.e., constant baseline hazard through time) and a frailty component to account for correlation within clusters. If $h(t_{ij} | x_{ij})$ is the hazard rate of the j^{th} individual in the i^{th} cluster with covariate values x_{ij} then this individual's hazard rate of an arbovirus infection can be written as:

$$h(t_{ij} | x_{ij}) = h_0(t_{ij}) \cdot \exp(\beta^T x_{ij} + W_i)$$

where $W_i \sim N(0, \sigma_c^2)$ is the random effect of the i^{th} cluster. Covariates included age, sex, and treatment status (SR or placebo). PE was estimated as $PE = (1 - \exp(\hat{\beta})) \times 100\%$, where $\hat{\beta}$ is the estimated regression coefficient for the intervention group and $\exp(\hat{\beta})$ is the estimated hazard ratio (HR) between SR and placebo. The null hypothesis of $PE = 0\%$ is equivalent to $\beta = 0$, which is tested by Wald's test $z = \beta/s$, where s is the estimated standard error of $\hat{\beta}$, at the 1-sided significance level of 5%.

A Poisson generalized linear regression was used to assess intervention impact on clinical disease, with an offset for the number of participant-days each participant spent in each cluster. No covariates were used and due to the small sample size, no random effects were incorporated.

Morrison AC et al. 17 June 2021

Indoor adult female *Ae. aegypti* abundance, blood-fed rates, and parity were tested through a difference-in-difference Poisson generalized linear mixed models. Collections conducted in 2016 were defined as ‘baseline’ and collections conducted in 2017 and 2018 were estimated as ‘post-baseline’. Each analysis accounted for month of year and year as fixed effects and contained a random effect by cluster. Model formulation details are in SI Sections 1.5.4-1.5.6.

The primary analysis conducted differs from that in the original SAP (SI SAP). Procedures called for yearly blood draws from children. To increase the number of qualifying participants, an expansion of the age range to all ages ≥ 2 yrs. The rolling enrollment resulted in substantial variation in time intervals between blood draws. Simple logistic regression, therefore, was inadequate. The decision to alter the primary analysis was discussed and agreed upon by the study statistician and the external DSMB statistician before outputs were unblinded to the DSMB statistician.

Results

STUDY POPULATION

A total of 2,215 persons were enrolled in the longitudinal cohort. Of these, 1,578 qualifying participants were included in the ITT analysis for seroconversion (Figure 3) representing a total of 196 ABV infections from 754 (1,090 paired samples) qualifying participants in the SR arm and 294 ABV infections from 824 (1,237 paired samples) qualifying participants in the placebo arm. Baseline covariates were balanced at both the cluster and individual level (Table 1).

Morrison AC et al. 17 June 2021

A total of 16,707 participants were followed for clinical disease, of which 16,683 were included in the ITT analysis (Figure S2). Baseline covariates for analysis of the secondary endpoint were balanced at both the cluster and individual level (Table S4).

INTERVENTION COVERAGE

The household participation rate (intervention deployed at some point during the study period) per cluster (SR and placebo) was of 56·6 % (SD = 10·5%), with slightly more participation in SR versus placebo clusters (58·8% v 54·5%, p-value = 0·336). In households consenting to receive intervention (SR or placebo), the mean percentage of days covered by an intervention at the cluster-level was 81·6% (SD = 3·9), with slightly higher coverage in households assigned to SR intervention (82·9%) compared to households in the placebo arm (80·3%), albeit insignificant (p-value = 0·153, Table S2, Figure S3). For all enrolled households, the mean percentage of days with an adequate intervention application rate (1 product per 9 m²) was 73·6% (SD = 9·1), with similar rates between SR and placebo clusters (72·7% versus 74·5%, p-value > 0·999, Table S2).

SPATIAL REPELLENT EFFICACY

The estimated PE of SR intervention was 34·1% (1-sided 95% CI lower limit, 6·9%; (Table 2). Reduction in the arbovirus infection hazard rate was significant at the 5% significance level (Test statistic: z=1·98, 1-sided p-value = 0·02). Baseline covariates included in the statistical model on the hazard of arbovirus infection in qualifying

Morrison AC et al. 17 June 2021

participants were age, which had statistically significant effects on the hazard of arbovirus infection in qualifying participants, and sex, which did not. Hazard rate increases by 4·6% for every one-year increase in age. Hazard rate decreases by 4·4% in males relative to females (Table 2). The originally proposed ITT mixed effects logistic regression analysis, which ignores differential participation duration across qualifying participants, produced a result consistent with those presented here; i.e., PE > 30% and statistical significance at the 5% level (Table 2).

The Kaplan-Meier curves of arbovirus infection for qualifying participants by cluster show considerable between-cluster variation (SR and placebo clusters) as evidenced by the wide spread of survival curves (Figure 4). For example, there were no arbovirus infections in qualifying participants in one placebo cluster; Cluster 7.2 had only 18 qualifying participants. Conversely, in Cluster 8.2 almost half of the qualifying participants with duration between serologic tests exceeded 15 months became infected (5/11). The duration between tests varied by participant and across clusters (Figure S4), resulting in some Kaplan-Meier curves being estimated beyond two years. In many of those clusters, the only participants that went over two years between blood sampling were universally found to have had an arboviral infection.

There were 96 disease cases detected, 51 in the SR arm and 45 in the placebo arm, from 10,793,792 participant days that appeared balanced between SR and placebo clusters (Table S4).

Morrison AC et al. 17 June 2021

The estimated reduction adult female *Ae. aegypti* abundance in clusters receiving SR intervention was 28·6% (1-sided 95% CI lower limit: 24·1%, test statistic: $z = -9·11$) (Table 3). Baseline mosquito abundance was balanced between treatment arms (Table S5) with post-baseline quantities estimated based on 47,518 and 43,417 household collections in SR and placebo arms, respectively. Baseline abundance averaged 0·277 (standard deviation [SD] 0·153) and 0·279 (SD 0·122) per house survey in SR and placebo arms, respectively, whereas post-baseline abundance averaged 0·276 (SD 0·091) and 0·391 (SD 0·142) in the SR and placebo arms, respectively (Table 3). There was a strong indication of seasonality, with z-scores comparing each month to the reference month of January being at least 6 away from 0 (Table S7). Overall, abundance trended lower in the SR clusters compared to the placebo clusters after intervention deployment from 2017-2019, the duration of the trial (Figure 5).

The estimated reduction in the rate of blood-fed *Ae. aegypti* collected inside houses was 12·4% (1-sided 95% CI lower limit: 4·2%, test statistic: $z = -2·430$) (Table 3). Baseline abundance of engorged *Ae. aegypti* was balanced treatment arms (Table S5) with post-baseline quantities estimated based on 9,257 and 11,496 mosquitoes assessed for blood-fed status in SR and placebo arms, respectively. Baseline abundance of blood-fed mosquitoes averaged 0·593 (standard deviation 0·440) and 0·536 (standard deviation 0·451) per collection in SR and placebo arms, respectively, and post-baseline rates averaged 0·606 (SD 0·460) and 0·634 (SD 0·447) in SR and placebo arms, respectively. There was no strong indication of seasonality (Table S8).

Morrison AC et al. 17 June 2021

330

331 There was no observed intervention effect (Table 3) or indication of seasonality
332 (Table S9) based on the parity rate of *Ae. aegypti* females.

333

334 ADVERSE EVENTS (AE) AND SERIOUS ADVERSE EVENTS (SAE).

335 There were 29 AEs reported during the trial (SI Section 2.8). Of these, three were
336 associated with blood draw (vasovagal response, two from SR and one from placebo
337 clusters) and 26 were consistent with transfluthrin (pyrethroid) exposure (22 from SR
338 and 4 from placebo clusters). Of the latter, the 26 affected individuals came from 18
339 households, often reporting different combinations of the following symptoms: allergic
340 response with itching and skin irritations (n=19; 15 from SR, four from placebo
341 clusters), dry mouth/bad taste (n=5, from SR clusters only), breathing issues (n=7,
342 from SR clusters only) including exacerbation of chronic bronchitis or asthma (n=2),
343 and headaches (n=4, from SR clusters only). No reported SAEs (deaths) were
344 deemed associated with the spatial repellent intervention.

345

346 Discussion

347 *Aedes*-borne viruses threats come from multiple viruses, which have expanding
348 regions of transmission and increasingly frequent epidemics. There is, therefore, a
349 growing unmet need for effective ABV disease prevention.⁹ Our cRCT provides the
350 first conclusive evidence of significant PE against human ABV infection by any
351 chemical-based vector control intervention, in this case a spatial repellent.

352

Morrison AC et al. 17 June 2021

PE was detected despite assumed dilution and contamination effects due to participant movement in and out of study clusters. Unlike a vaccine, this intervention protects the study participant in their own home or another protected home within their neighborhood (i.e. Study Cluster), but does not provide continuous protection once they leave treated houses. Our cohort, tested for ABV seroconversion, was comprised principally of children ≤ 17 years of age, most who attended schools which have been shown to be of lower risk of *Ae. aegypti* infestation than residential sites in Iquitos.²³ Our outcome was demonstrated in an operational context, reflecting complex interactions among ongoing Ministry of Health interventions across the study area, imperfect coverage at the household-level (rooms closed to intervention, homeowner removal and/or loss of intervention), <100% household participation within clusters, and suggestion of pyrethroid resistance in the local *Ae. aegypti* population.²⁴(SI section 2.7) Reduced risk of ABV infection was associated with a significant reduction in indoor female *Ae. aegypti* abundance and blood feeding. Although entomological outcomes were modest, these effects are consistent with the expected mode of action of SRs; i.e., deterrence from house entry and/or interfering with human-biting.^{12,25} Our entomological data will help guide indicators for next-generation product development.

Our results support SRs as a flexible class of vector control products with positive public health impact not limited to ABV diseases. Transfluthrin-¹⁵ and metofluthrin-based^{16,26} mosquito coils have been shown to reduce malaria and the same spatial repellent device used in our Iquitos trial reduced malaria infections in an Indonesia

Morrison AC et al. 17 June 2021

cRCT.¹⁵ Together, these results highlight the potential for SRs to reduce a variety of vector-borne diseases, augment existing public health efforts and be an effective component of vector control intervention strategies. To help guide implementation and programmatic scale-up, additional assessments, which have already begun,^{27–30} are needed.

Our Peru cRCT is one of two trials recommended by the WHO for assessing public health value and developing global health policy for the SR intervention class.³¹ Our study was powered to detect a 30% reduction in ABV infection risk. During the trial period, dengue prevalence was lower than previous years and a Zika epidemic occurred in 2016.³² This uncertainty is typical of ABV transmission, making powering of cRCTs challenging and helps explain why, until now, ABV cRCTs with epidemiological outcomes have been rare.³³ We used seroconversion as our primary endpoint of PE to address this challenge. In our setting, powering a trial based on clinically apparent ABV disease would not be logistically feasible.

Fully integrating vector control into ABV disease prevention programs will require quantitative guidance based on quantitative measures of the impact from each intervention component. Ministries of Health, local to national governments and non-governmental organizations can use our trial results as an evidence-base for informed application of SRs. Considering the growing ABV public health threat, difficulties of developing vaccines against multiple viruses and past, poorly informed

Morrison AC et al. 17 June 2021

vector control failures,⁹ enhanced ABV disease prevention will benefit greatly from interventions with proven public health value.

Data sharing

De-identified analytical datasets, including deidentified participant data, data dictionaries and analytical codes, will be made available with publication upon request to RCR at bcreiner@uw.edu. Open-access distribution of the data will fall under the terms of the Creative Commons Attribution (CC-BY) License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Acknowledgements

We extend sincere appreciation to DSMB members: Dennis Shanks, Chris Drakeley, and Neal Alexander for assurances on data integrity and safety assessments. We thank the WHO Vector Control Advisory Group (VCAG) for their comments during project assessments. We are grateful for the efforts of Marianne Kent, Program Coordinator at the University of Notre Dame, for her administrative, and logistical support of the program, as well as, Brett Fox of the University of Notre Dame Center for Research Computing for assisting with central database development for data verification. We thank Kristina Davis and Matthew Sisk of the University of Notre Dame Center for Research Computing and Hesburgh Libraries, respectively, for their assistance in graphic development. We acknowledge Audrey Lenhart of the Centers for Disease Control and Prevention (CDC) in Atlanta, GA USA and J. Kevin Baird of

Morrison AC et al. 17 June 2021

the Eijkman-Oxford Clinical Research Unit, Jakarta, Indonesia and Nuffield Department of Medicine, Centre for Tropical Medicine, University of Oxford, Oxford, United Kingdom for their role on the Scientific Advisory Committee.

We express our gratitude to the Bill and Melinda Gates Foundation for their long-term generosity and support of spatial repellent product evaluation and development, especially Kate Aultman, Dan Strickman, and Alan Magill. We are deeply grateful to SC Johnson for providing integral industry and product expertise including the independent funding of the development, manufacturing, delivery, and shipment of the intervention (SR and placebo) used in the study. SC Johnson provided expertise in ensuring intervention quality, storage, application and disposal assurances throughout the trial.

We thank the residents of Iquitos for their support and participation in this study and willingness to allow this study to be conducted in their community. We greatly appreciate support of the Loreto Regional Health Department including Drs. Hugo Rodriguez-Ferruci, Christian Carey, Carlos Alvarez, and Lic. Wilma Casanova Rojas, who facilitated our work in Iquitos. We thank the NAMRU-6 Virology and Emerging Infections Department (VEID) leadership who provided institutional support, IRB guidance, and support supervising field staff. We appreciate the careful commentary and advice provided by the NAMRU-6 IRB and Research Administration Program for the duration of this study. We thank the NAMRU-6 VEID field who provided daily support through the duration of the project and without whom the recruitment of acute

Morrison AC et al. 17 June 2021

dengue cases would not have been possible. In particular, we thank Cecilia Gonzales, Gloria Talledo, and Gabriela Vasquez de la Torre for their administrative support of the project.

Author contributions

Data were gathered by the field team in Iquitos (ACM, WHE, HA, IB, CS, and ABK); laboratory testing by CG, PB, and AH; insecticide resistance testing by GMV, KEV, and CFM; and human use issues were managed by ACM, SAJ, and WRC. ML developed a Zika virus PCR assay used in the study. CDA provided Ministry of Health entomological information and coordinated activities with Iquitos field teams. The NAMRU-6 supervisory team in Lima included MS, SAJ, WRC, EJA, and RHD. CM provided data management and ZIKV MNT laboratory testing. Statistical analysis was conducted by RCR. The first draft of the manuscript was written by ACM, RCR, TWS, and NLA, with revision following comments from all the authors.

Copyright statement

SAJ, WRC, EJA and RDH are military service members and ACM, HA, CG, IB, CS, GMV, KE, CF, AAH, and MES are employees of the U.S. Government. This work was prepared as part of their official duties. Title 17 U.S.C. §105 provides that “Copyright protection under this Title is not available for any work of the United States Government”. Title 17 U.S.C. §101 defines a U.S. Government work as a work prepared by a military service member or employee of the U.S. Government as part of that person’s official duties.

Morrison AC et al. 17 June 2021

467

468 Disclaimer

469 The views expressed in this article are those of the author and do not necessarily
470 reflect the official policy or position of the Department of the Navy, Department of
471 Defense, nor the U.S. Government.

472

473 Financial disclosure statement

474 This study was funded by the Bill and Melinda Gates Foundation (BMGF) to the
475 University of Notre Dame (Grant# OPP1081737). Further support was provided by
476 the Defense Threat Reduction Agency (DTRA), Military Infectious Disease Research
477 Program (MIDRP, S0520_15_LI and S0572_17_LI), and the U.S. National Institute of
478 Allergy and Infectious Diseases (NIH/NIAID) award number P01 AI098670. SC
479 Johnson used internal company financial resources for the development,
480 manufacturing, delivery, and shipment of the intervention (SR and placebo) used in
481 the study.

482

483 Competing interests

484 The authors have declared that no competing interests exist.

Morrison AC et al. 17 June 2021

References

- 1 Murray CJL, Barber RM, Foreman KJ, *et al.* Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990–2013: quantifying the epidemiological transition. *Lancet* 2015; **386**: 2145–91.
- 2 Stanaway JD, Shepard DS, Undurraga EA, *et al.* The global burden of dengue: an analysis from the Global Burden of Disease Study 2013. *Lancet Infect Dis* 2016; **16**: 712–23.
- 3 Bhatt S, Gething PW, Brady OJ, *et al.* The global distribution and burden of dengue. *Nature* 2013; **496**: 504–7.
- 4 Parks W, Lloyd L. Planning social mobilization and communication for dengue fever prevention and control. Geneva: WHO, 2004.
- 5 Esu E, Lenhart A, Smith L, Horstick O. Effectiveness of peridomestic space spraying with insecticide on dengue transmission; systematic review. *Trop Med Int Health* 2010; **15**: 619–31.
- 6 Horstick O, Runge-Ranzinger S, Nathan MB, Kroeger A. Dengue vector-control services: how do they work? A systematic literature review and country case studies. *Trans R Soc Trop Med Hyg* 2010; **104**: 379–86.
- 7 Bowman LR, Donegan S, McCall PJ. Is Dengue Vector Control Deficient in Effectiveness or Evidence?: Systematic Review and Meta-analysis. *PLoS Negl Trop Dis* 2016; **10**: e0004551.
- 8 Morrison AC, Zielinski-Gutierrez E, Scott TW, Rosenberg R. Defining challenges and proposing solutions for control of the virus vector *Aedes aegypti*. *PLoS Med* 2008; **5**: e68.
- 9 Achee NL, Gould F, Perkins TA, *et al.* A critical assessment of vector control for dengue prevention. *PLoS Negl Trop Dis* 2015; **9**: e0003655.
- 10 Andersson N, Nava-Aguilera E, Arostegui J, *et al.* Evidence based community mobilization for dengue prevention in Nicaragua and Mexico (Camino Verde, the Green Way): cluster randomized controlled trial. *BMJ* 2015; **351**: h3267.
- 11 Utarini A, Indriani C, Ahmad RA, *et al.* Efficacy of Wolbachia-infected mosquito deployments for the control of dengue. *N Engl J Med* 2021; **384**: 2177–86.

Morrison AC et al. 17 June 2021

- 516 12 Achee NL, Bangs MJ, Farlow R, *et al.* Spatial repellents: from discovery and
517 development to evidence-based validation. *Malar J* 2012; **11**: 164.
- 518 13 World Health Organization. WHO pesticide evaluation scheme. World Health
519 Organization, 2013 <http://www.who.int/iris/handle/10665/78142>.
- 520 14 WHO | Vector Control Advisory Group. 2020; published online Oct 6.
521 <https://www.who.int/vector-control/vcag/en> (accessed Nov 26, 2020).
- 522 15 Hill N, Zhou H, Wang P, Guo X, Carneiro I, Moore SJ. A household randomized,
523 controlled trial of the efficacy of 0.03% transfluthrin coils alone and in combination
524 with long-lasting insecticidal nets on the incidence of *Plasmodium falciparum* and
525 *Plasmodium vivax* malaria in Western Yunnan Province, China. *Malaria Journal*.
526 2014; **13**: 208.
- 527 16 Syafruddin D, Asih PBS, Rozi IE, *et al.* Efficacy of a Spatial Repellent for Control
528 of Malaria in Indonesia: A Cluster-Randomized Controlled Trial. *Am J Trop Med Hyg*
529 2020; published online May 18. DOI:10.4269/ajtmh.19-0554.
- 530 17 Vazquez-Prokopec GM, Bisanzio D, Stoddard ST, *et al.* Using GPS technology to
531 quantify human mobility, dynamic contacts and infectious disease dynamics in a
532 resource-poor urban environment. *PLoS One* 2013; **8**: e58802.
- 533 18 Vazquez-Prokopec GM, Stoddard ST, Paz-Soldan V, *et al.* Usefulness of
534 commercially available GPS data-loggers for tracking human movement and
535 exposure to dengue virus. *Int J Health Geogr* 2009; **8**: 68.
- 536 19 Gunning CE, Okamoto K, Astete H, *et al.* Efficacy of *Aedes aegypti* control by
537 indoor Ultra Low Volume (ULV) insecticide spraying in Iquitos, Peru. *PLoS Negl Trop*
538 *Dis* 2018; **12**: e0006378.
- 539 20 R Core Team. R: A language and environment for statistical computing. R
540 Foundation for Statistical Computing. Vienna, Austria, 2019 <http://www.R-project.org/>.
- 541 21 Bates D, Mächler M, Bolker B, Walker S. Fitting Linear Mixed-Effects Models
542 using lme4. arXiv [stat.CO]. 2014; published online June 23.
543 <http://arxiv.org/abs/1406.5823>.
- 544 22 Therneau TM. A Package for Survival Analysis in S. version 2.38. 2015; published
545 online Sept 28. <http://cran.r-project.org/package=survival> (accessed Jan 19, 2021).
- 546 23 Morrison AC, Sihuinchu M, Stancil JD, *et al.* *Aedes aegypti* (Diptera: Culicidae)
547 production from non-residential sites in the Amazonian city of Iquitos, Peru. *Ann Trop*
548 *Med Parasitol* 2006; **100 Suppl 1**: S73–86.

Morrison AC et al. 17 June 2021

- 549 24 Palomino-Salcedo M. [Estado de susceptibilidad de la población natural de Aedes
550 aegypti a los insecticidas en Punchana-Iquitos, Región Loreto (Noviembre 2014).
551 Instituto Nacional de Salud, Peru, 2014.
- 552 25 Norris E, Coats J. Current and future repellent technologies: The potential of
553 spatial repellents and their place in mosquito-borne disease control. *Int J Environ Res*
554 *Public Health* 2017; **14**: 124.
- 555 26 Syafruddin D, Bangs MJ, Sidik D, et al. Impact of a spatial repellent on malaria
556 incidence in two villages in Sumba, Indonesia. *Am J Trop Med Hyg* 2014; **91**: 1079–
557 87.
- 558 27 Liverani M, Charlwood JD, Lawford H, Yeung S. Field assessment of a novel
559 spatial repellent for malaria control: a feasibility and acceptability study in Mondulkiri,
560 Cambodia. *Malar J* 2017; **16**: 412.
- 561 28 Masalu JP, Finda M, Okumu FO, et al. Efficacy and user acceptability of
562 transfluthrin-treated sisal and hessian decorations for protecting against mosquito
563 bites in outdoor bars. *Parasit Vectors* 2017; **10**: 197.
- 564 29 Paz-Soldan VA, Plasai V, Morrison AC, et al. Initial assessment of the
565 acceptability of a Push-Pull Aedes aegypti control strategy in Iquitos, Peru and
566 Kanchanaburi, Thailand. *Am J Trop Med Hyg* 2011; **84**: 208–17.
- 567 30 Jumbam DT, Stevenson JC, Matoba J, et al. Knowledge, attitudes and practices
568 assessment of malaria interventions in rural Zambia. *BMC Public Health* 2020; **20**:
569 216.
- 570 31 World Health Organization. The evaluation process for vector control products.
571 World Health Organization, 2017 <https://apps.who.int/iris/handle/10665/255644>
572 (accessed Dec 2, 2020).
- 573 32 [https://www.paho.org/hq/dmdocuments/2017/2017-phe-zika-situation-report-](https://www.paho.org/hq/dmdocuments/2017/2017-phe-zika-situation-report-per.pdf)
574 [per.pdf](https://www.paho.org/hq/dmdocuments/2017/2017-phe-zika-situation-report-per.pdf) (Accessed Dec 2, 2020).
- 575 33 Anders KL, Cutcher Z, Kleinschmidt I, et al. Cluster-Randomized Test-Negative
576 Design Trials: A Novel and Efficient Method to Assess the Efficacy of Community-
577 Level Dengue Interventions. *Am J Epidemiol* 2018; **187**: 2021–8.

Morrison AC et al. 17 June 2021

Figure 1. Location of 26 study clusters in Iquitos and Punchana Districts, Loreto Department, Iquitos, Peru. Each cluster consisted of ca. 140 households with an average distance of 300m between clusters.

Morrison AC et al. 17 June 2021

Figure 2. Study timeline. Top panel: Human blood-sampling, disease surveillance, and entomological monitoring in relation to deployment of the spatial repellent intervention. Bottom panel: Intervention roll-out between August-December 2016 by cluster. Horizontal numbers correspond to cluster numbers shown in Figure 1.

Morrison AC et al. 17 June 2021

Figure 3. Allocation and follow-up of the longitudinal cohort population during three blood collection periods (Baseline [B], First [F] and Second/Final [S]). The majority (62%) of participants provided samples at each collection period, whereas some only participated during year 1 (B-F) or year 2 (F-S). Participants with a single sample were lost to follow-up and four individuals moved or had two houses located in the spatial repellent and placebo clusters are shown as removed at the baseline period for clarity.

Morrison AC et al. 17 June 2021

Figure 4. Kaplan-Meier curves of arbovirus infection for 13 spatial repellent (SR) and 13 placebo clusters in qualifying participants measured by seroconversion (primary endpoint) by cluster.

604 **Figure 5.** Mean densities of adult female *Aedes aegypti* collected per household survey in 13 spatial repellent (SR) and
605 13 placebo clusters by study month. Shaded areas represent the 95% Confidence Interval around the mean.

606

607

608 **Table 1.** Summary of baseline characteristics, for qualifying participants of the intent-to-treat (ITT) longitudinal cohort
 609 population in spatial repellent (SR) and placebo arms. Qualifying participants were defined as individuals in a participating
 610 house who were seronegative or had a monotypic DENV antibody response when they entered the trial.

Individual-Level		
Variable	SR (n=898)	Placebo (n=952)
Age in years (mean±sd) (min, max)	10·88±4·62 (2, 47)	10·19±4·39 (2, 22)
Sex (% male)	51·6%	55·0%
Duration in years between samples (mean±sd) (min, max)	1·15±0·42 (0·02, 2·29)	1·16±0·43 (0·01, 2·35)
No. qualifying participant observations	1,090	1,237
No. of arbovirus seroconversions	196	294
Cluster-Level		
Variable	SR (n=13)	Placebo (n=13)
Cluster population (mean±sd) (min, max)	58·2±30·4 (21, 124)	73·5±35·3 (12, 132)
Baseline susceptibility (mean±sd) (min, max)	81·0%±12·8% (54·7%, 98·1%)	84·9%±6·3% (73·3%, 92·5%)

611

Table 2. Protective efficacy (PE) estimates from intent to treat (ITT) analyses for the spatial repellent intervention against *Aedes*-borne virus infection in qualifying participants measured by seroconversion (primary endpoint), including covariate effects.

ITT analysis	Hazard rate ratio (95% CI)	PE (%) (95% CI)	One-sided p-value	Covariate	Odds ratio (95% CI)	Two-sided p-value
Survival analysis	0·659 (-∞,0·931)	34·1 (6·9,∞)	0·024			
				Age	1·046 (1·029-1·063)	6·8 x 10 ⁻⁶
				Male	0·956 (0·821-1·112)	0·62
ITT analysis	Odds ratio (95% CI)	PE (%) (95% CI)	One-sided p-value	Covariate	Odds ratio (95% CI)	Two-sided p-value
Odds reduction	0·547 (-∞,0·883)	45·3 (11·7,∞)	0·019			
				Age	1·071 (1·042-1·100)	6·9 x 10 ⁻⁷
				Male	0·950 (0·767-1·177)	0·64
Odds reduction on including 9–15-month sampling intervals	0·577 (-∞,0·879)	42·3 (12·1,∞)	0·016			
				Age	1·065 (1·028-1·103)	0·0005
				Male	0·970 (0·767-1·299)	0·779

Table 3. Rate reduction summary of indoor adult female *Aedes aegypti* abundance, blood-fed female abundance, and parity rates (secondary endpoints) for primary (ITT) and secondary analyses (PP). No correction for multiple testing was performed for secondary endpoint analyses and, as such, in accordance with CONSORT guidelines p-values are not presented.

Indicator	Statistics	2016 Baseline ¹		Cluster-specific Baseline ²	
		ITT	PP	ITT	PP
Indoor adult female <i>Aedes aegypti</i> abundance	Rate ratio (95% one-sided CI)	0.714 (-∞, 0.759)	0.737 (-∞, 0.784)	0.599 (-∞, 0.633)	0.607 (-∞, 0.641)
	Rate reduction (%) (95% one-sided CI)	28.6 (24.1, ∞)	26.3 (16.2, ∞)	40.1 (36.7, ∞)	39.3 (35.9, ∞)
Blood-fed female <i>Aedes aegypti</i> abundance	Rate ratio (95% one-sided CI)	0.876 (-∞, 0.958)	0.876 (-∞, 0.958)	0.908 (-∞, 0.985)	0.929 (-∞, 1.06)
	Rate reduction (%) (95% one-sided CI)	12.4 (4.2, ∞)	12.4 (4.2, ∞)	9.20 (1.49, ∞)	7.10 (-6, ∞)
<i>Aedes aegypti</i> parity rate	Rate ratio (95% one-sided CI)	0.922 (-∞, 1.057)	0.921 (-∞, 1.056)	0.928 (-∞, 1.058)	0.909 (-∞, 0.986)
	Rate reduction (%) (95% one-sided CI)	7.75 (-5.70, ∞)	7.87 (-5.60, ∞)	7.24 (-5.80, ∞)	9.10 (-1.2, ∞)

¹ Intent to treat (ITT, primary analysis) and per protocol (PP, secondary analysis) mixed effects difference-in-difference (DID) Poisson regression specifying measurements made throughout 2016 as 'baseline', with post-2016 measurements as 'post-baseline.' PP analysis only considering houses with SR application rates meeting manufactures specifications $\geq 75\%$ of the days between sequential blood sampling (designated PP-1).

² ITT and PP mixed effects DID Poisson regression specifying measurements made in 2016 up to the first date of intervention deployed in each cluster as 'baseline' with all measurements following that date as 'post-baseline' for that cluster, even for houses that did not enroll until 2017 or later. PP analysis only considering houses with SR application rates meeting manufactures specifications $\geq 75\%$ of the days between sequential blood sampling (designated PP-1).